Ashok Ghoghari

Ashok Ghoghari

Auto-generated profile, based on publicly available information

Ashok Ghoghari

Bioanalytical Laboratory, Zydus Research Center, Ahmedabad, 382210, Gujarat, India

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2006 in Chromatographia
Verified
Journal Article
Closed access
PDF file
AGA. M. Ghoghari
A. M. Ghoghari
MRM. Rajani
M. Rajani

1 December 2021 in Bioanalysis
Verified
Journal Article
Closed access
AGAshok M Ghoghari
Ashok M Ghoghari
HPHarilal V Patel
Harilal V Patel
NNNisarg N Nayak
Nisarg N Nayak
TMTariq H Mansuri
Tariq H Mansuri
SPSoma M Pillai
Soma M Pillai
DPDeven V Parmar
Deven V Parmar
Aim: ZY-19489 is a new antimalarial drug candidate and selective LC–MS/MS method was established for estimation of ZY-19489 and its metabolite in human plasma. Materials & methods: LLE was employed for extraction, mass spectrometric quantification performed using positive ionization mode and DCP-IMP was used as an internal standard. The chromatographic separation was achieved using mobile phase 5 mM ammonium formate in water and 0.1% v/v ammonia solution in methanol: acetonitrile (90: 10%, v/v) and column Agilent Zorbex Extended C18, 3.5 μm, 100 × 4.6 mm with a 6-min run time. Results: The calibration curve of ZY-19489 was linear over range 1–500 ng/ml and 2–200 ng/ml for metabolite. Assay was reproducible, selective and devoid of matrix effect. Conclusion: The validated assay was implemented for clinical sample analysis derived from healthy human subjects and parasitemia-induced subjects.

26 April 2017 in Drug Research
Verified
Journal Article
Closed access
PDF file
HPHarilal Patel
Harilal Patel
PPPrakash Patel
Prakash Patel
CBChandrakant Bhatt
Chandrakant Bhatt
AGAshok Ghoghari
Ashok Ghoghari
UPUrvesh Patel
Urvesh Patel
NSNuggehally R. Srinivas
Nuggehally R. Srinivas
The aim of the preclinical investigation was to obtain single dose pharmacokinetics in dogs from 2 different oral cholecalciferol formulations using corrective measures to overcome the interference of endogenous cholecalciferol. 6 dogs were fasted overnight and the following day received 60 000 IU dose cholecalciferol [reference, Eris®, vs. test, Sunbless®] by oral dosing. Blood samples were collected on day 0 (baseline establishment) and after dosing on day 1 up to 28 days. The serum samples were extracted using protein precipitation/solid phase extraction and analysed to determine cholecalciferol by LC-MS/MS assay with calibrators prepared from cholecalciferol free serum. Standard pharmacokinetic analysis was carried out to assess pharmacokinetic parameters. An un-paired t-test was employed for comparing statistical significance between formulations. Serum cholecalciferol concentration vs. time profiles for the 2 formulations was almost superimposable. None of the pharmacokinetic parameters showed statistically significant differences (p>0.05) between the 2 treatments. For example: Cmax (ng/mL) and AUCinf (ng.h/mL) derived after the baseline corrections were 708.65 and 38 877.18 for reference and 743.71 and 40 665.51 for test, respectively. Pharmacokinetics of cholecalciferol was comparable between reference vs. test formulations. The procedures, baseline correction and employment of cholecalciferol devoid serum, can be readily adopted in future pharmacokinetic studies in animals or humans.

1 November 2021 in Journal of Chromatography B
Verified
Journal Article
Closed access
AGAshok Ghoghari
Ashok Ghoghari
CBChandrakant Bhatt
Chandrakant Bhatt
KPKuldip Patel
Kuldip Patel
AJAnil Jha
Anil Jha
HPHarilal Patel
Harilal Patel
PPPankaj Patel
Pankaj Patel

1 September 2022 in Bioanalysis
Verified
Journal Article
Closed access
AGAshok M Ghoghari
Ashok M Ghoghari
HPHarilal V Patel
Harilal V Patel
MJMukul R Jain
Mukul R Jain